Your browser doesn't support javascript.
BNT162b2 vaccination induces durable SARS-CoV-2-specific T cells with a stem cell memory phenotype.
Guerrera, Gisella; Picozza, Mario; D'Orso, Silvia; Placido, Roberta; Pirronello, Marta; Verdiani, Alice; Termine, Andrea; Fabrizio, Carlo; Giannessi, Flavia; Sambucci, Manolo; Balice, Maria Pia; Caltagirone, Carlo; Salvia, Antonino; Rossini, Angelo; Battistini, Luca; Borsellino, Giovanna.
  • Guerrera G; Neuroimmunology Unit, Santa Lucia Foundation IRCCS, Rome, Italy.
  • Picozza M; Neuroimmunology Unit, Santa Lucia Foundation IRCCS, Rome, Italy.
  • D'Orso S; Neuroimmunology Unit, Santa Lucia Foundation IRCCS, Rome, Italy.
  • Placido R; Neuroimmunology Unit, Santa Lucia Foundation IRCCS, Rome, Italy.
  • Pirronello M; Neuroimmunology Unit, Santa Lucia Foundation IRCCS, Rome, Italy.
  • Verdiani A; Neuroimmunology Unit, Santa Lucia Foundation IRCCS, Rome, Italy.
  • Termine A; Data Science Unit, Santa Lucia Foundation IRCCS, Rome, Italy.
  • Fabrizio C; Data Science Unit, Santa Lucia Foundation IRCCS, Rome, Italy.
  • Giannessi F; Neuroimmunology Unit, Santa Lucia Foundation IRCCS, Rome, Italy.
  • Sambucci M; Neuroimmunology Unit, Santa Lucia Foundation IRCCS, Rome, Italy.
  • Balice MP; Clinical Microbiology Laboratory, Santa Lucia Foundation IRCCS, Rome, Italy.
  • Caltagirone C; Department of Clinical and Behavioral Neurology, Santa Lucia Foundation IRCCS, Rome, Italy.
  • Salvia A; Medical Services, Santa Lucia Foundation IRCCS, Rome, Italy.
  • Rossini A; Medical Services, Santa Lucia Foundation IRCCS, Rome, Italy.
  • Battistini L; Neuroimmunology Unit, Santa Lucia Foundation IRCCS, Rome, Italy.
  • Borsellino G; Neuroimmunology Unit, Santa Lucia Foundation IRCCS, Rome, Italy.
Sci Immunol ; 6(66): eabl5344, 2021 Dec 24.
Article in English | MEDLINE | ID: covidwho-1494931
ABSTRACT
Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is effective in preventing hospitalization from severe COVID-19. However, multiple reports of breakthrough infections and of waning antibody titers have raised concerns on the durability of the vaccine, and current vaccination strategies now propose administration of a third dose. Here, we monitored T cell responses to the Spike protein of SARS-CoV-2 in 71 healthy donors vaccinated with two doses of the Pfizer-BioNTech mRNA vaccine (BNT162b2) for up to 6 months after vaccination. We found that vaccination induced the development of a sustained anti-viral CD4+ and CD8+ T cell response. These cells appeared before the development of high antibody titers, displayed markers of immunological maturity and stem cell memory, survived the physiological contraction of the immune response, and persisted for at least 6 months. Collectively, these data show that vaccination with BNT162b2 elicits an immunologically competent and long-lived SARS-CoV-2­specific T cell population.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Stem Cells / CD4-Positive T-Lymphocytes / CD8-Positive T-Lymphocytes / SARS-CoV-2 / COVID-19 / BNT162 Vaccine / Memory T Cells / Immunity, Cellular Type of study: Prognostic study Topics: Vaccines Limits: Female / Humans / Male Language: English Journal: Sci Immunol Year: 2021 Document Type: Article Affiliation country: Sciimmunol.abl5344

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Stem Cells / CD4-Positive T-Lymphocytes / CD8-Positive T-Lymphocytes / SARS-CoV-2 / COVID-19 / BNT162 Vaccine / Memory T Cells / Immunity, Cellular Type of study: Prognostic study Topics: Vaccines Limits: Female / Humans / Male Language: English Journal: Sci Immunol Year: 2021 Document Type: Article Affiliation country: Sciimmunol.abl5344